HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to stall breast cancer growth
Disease control OngoingThis phase 3 trial tests whether adding capivasertib to standard fulvestrant therapy can slow cancer growth in people with advanced HR+/HER2- breast cancer. About 818 participants whose cancer worsened after hormone therapy will receive either the combination or a placebo plus fu…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug targets Gene-Mutated breast cancer in phase 2 trial
Disease control OngoingThis Phase 2 study tests a drug called zelenectide pevedotin in 66 people with advanced breast cancer that has a specific gene change (NECTIN4 amplification). The study includes two groups: one with hormone receptor-positive/HER2-negative cancer and one with triple-negative breas…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for Hard-to-Treat breast cancer: targeted pill plus hormone therapy shows promise
Disease control OngoingThis phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New injection aims to halt ovarian function in breast cancer fight
Disease control OngoingThis phase 3 study tests a 3-month injection (TOL2506) to temporarily stop ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The goal is to see if it works well with hormone therapy (tamoxifen or aromatase inhibitors) to control the cancer. About 250 …
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC